1. Home
  2. DKI vs SNGX Comparison

DKI vs SNGX Comparison

Compare DKI & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DKI

DarkIris Inc. Class A Ordinary Shares

HOLD

Current Price

$4.80

Market Cap

10.1M

Sector

N/A

ML Signal

HOLD

Logo Soligenix Inc.

SNGX

Soligenix Inc.

HOLD

Current Price

$0.41

Market Cap

5.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DKI
SNGX
Founded
2018
1987
Country
Hong Kong
United States
Employees
19
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.1M
5.6M
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
DKI
SNGX
Price
$4.80
$0.41
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
76.1K
2.6M
Earning Date
05-11-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
57.03
EPS
N/A
N/A
Revenue
N/A
$119,371.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$0.28
52 Week High
$11.80
$6.23

Technical Indicators

Market Signals
Indicator
DKI
SNGX
Relative Strength Index (RSI) 47.50 42.15
Support Level $0.39 $0.41
Resistance Level $6.80 $1.48
Average True Range (ATR) 0.80 0.03
MACD -0.22 0.00
Stochastic Oscillator 16.15 40.64

Price Performance

Historical Comparison
DKI
SNGX

About DKI DarkIris Inc. Class A Ordinary Shares

Darkiris Inc is a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games via various third-party digital storefronts. Its activities encompass including game design, programming and graphics, as well as distribution and operation of mobile games on various platforms. Its core product offerings are Games Development; develop, market and distribute its self-developed mobile games; and Games Publishing and Operation. It publish and operate its self-developed mobile games and mobile games it license from other game developers.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).

Share on Social Networks: